PT - JOURNAL ARTICLE AU - Chun Yat Chu AU - Gert Marais AU - Christoffel Opperman AU - Deelan Doolabh AU - Arash Iranzadeh AU - Carisa Marais AU - Helen Cox AU - Carolyn Williamson AU - Diana Hardie AU - Adrian Brink TI - Improved performance of saliva for the detection of the B.1.351 variant in South Africa AID - 10.1101/2021.03.29.21254563 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.29.21254563 4099 - http://medrxiv.org/content/early/2021/03/31/2021.03.29.21254563.short 4100 - http://medrxiv.org/content/early/2021/03/31/2021.03.29.21254563.full AB - Assessment of the unknown performance of saliva for the detection of the novel SARS-CoV-2 variant of concern (VOC) B.1.351 (501Y.V2) lineage is essential as saliva has been shown to be an equivalent, less invasive and a less costly alternative to nasopharyngeal swabs for the molecular detection of SARS-CoV-2 infection in pre-variant studies. Between 1st August 2020 and 16th January 2021, we enrolled 410 eligible ambulatory participants who presented to Groote Schuur Hospital (GSH) in Cape Town, South Africa for SARS-CoV-2 testing. Of these, 300 were enrolled prior to, and 110 after, the initial detection and replacement of wild-type by the B.1.351 variant. All participants provided a supervised self-collected mid-turbinate (MT) and saliva (SA) swab, in addition to the standard HCW collected NP swab which were all tested by RT-PCR in an accredited diagnostic laboratory. Positive percent agreement to NP swab for SA swabs pre- and post-variant were 51.5% and 72.5% respectively while these values for MT swabs were 75.8% and 77.5%. The negative percent agreement for all swab types during all periods was >98%. The basis for this marked improvement of SA swabs as a diagnostic sample for B.1.351 virus is still being investigated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementUniversity of Cape Town Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Cape Town - Faculty of Health Sciences Human Research Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesno additional data provided